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Abstract: Bacterial-derived lipopolysaccharides (LPS) can cause defective intestinal 
barrier function and play an important role in the development of inflammatory bowel 
disease. In this study, a nanocarrier based on chitosan and fucoidan was developed for oral 
delivery of berberine (Ber). A sulfonated fucoidan, fucoidan-taurine (FD-Tau) conjugate, 
was synthesized and characterized by Fourier transform infrared (FTIR) spectroscopy.  
The FD-Tau conjugate was self-assembled with berberine and chitosan (CS) to form  
Ber-loaded CS/FD-Tau complex nanoparticles with high drug loading efficiency. 
Berberine release from the nanoparticles had fast release in simulated intestinal fluid (SIF,  
pH 7.4), while the release was slow in simulated gastric fluid (SGF, pH 2.0). The effect of 
the berberine-loaded nanoparticles in protecting intestinal tight-junction barrier function 
against nitric oxide and inflammatory cytokines released from LPS-stimulated macrophage 
was evaluated by determining the transepithelial electrical resistance (TEER) and paracellular 
permeability of a model macromolecule fluorescein isothiocyanate-dextran (FITC-dextran) 
OPEN ACCESS 
Mar. Drugs 2014, 12 5678 
 
 
in a Caco-2 cells/RAW264.7 cells co-culture system. Inhibition of redistribution of tight 
junction ZO-1 protein by the nanoparticles was visualized using confocal laser scanning 
microscopy (CLSM). The results suggest that the nanoparticles may be useful for local 
delivery of berberine to ameliorate LPS-induced intestinal epithelia tight junction disruption, 
and that the released berberine can restore barrier function in inflammatory and injured 
intestinal epithelial. 
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1. Introduction 
Intestinal epithelial tight junctions provide the barrier function in preventing the invasion of bacterial 
endotoxin and subsequent contact with the immune system. Bacterial-derived lipopolysaccharides 
(LPS) can cause defective intestinal barrier function which increases the risk of development of 
inflammatory bowel disease [1]. Berberine (Ber) is an isoquinoline alkaloid in the Berberis species 
which has many antimicrobial activities against fungal, bacterial and viral infections [2]. Berberine also 
exhibited potential anti-inflammatory activity both in vitro and in vivo [3]. Several studies reported that 
berberine promoted tightness of the intestinal epithelial tight junction (TJ) barrier and ameliorated TJ 
barrier impairment by suppressing the production of proinflammatory cytokines [4–8]. However, its 
application in oral administration is limited mainly due to the low local concentration, short residence 
time, and poor absorption in the intestinal tract [9]. To overcome these problems, the development of a 
drug delivery system with both mucoadhesive and pH-sensitive properties is required to increase the 
local berberin concentration by reducing the dissolution rate of berberin in gastric juice and also by 
prolonging the residence time of berberin in intestinal mucus. Nanocarriers have been used to localize 
berberine to the gastric epithelium for the treatment of H. pylori infection [10,11]. 
Chitosan (CS), a linear polysaccharide obtained by partial deacetylation of chitin, has been widely 
used in the biomedical field and drug delivery applications [12–14]. The naturally occurring polymer 
has many favorable characteristics, including mucoadhesive and pH-sensitive properties [15,16]. 
Chitosan-based nanoparticles have gained increasing attention for their efficient oral delivery of 
proteins and drugs [17,18]. Fucoidan (FD) is extracted from marine brown seaweed that has a backbone 
composed of sulfated esters of fucose and glucuronic acid or other monosaccharides [19]. Fucoidan 
can exert a wide variety of pharmacological activities, such as anti-inflammatory, anti-angiogenic, 
antitumor, and antithrombotic activities [20,21]. Suppression of inflammatory cytokine production in 
the Caco-2/RAW264.7 co-culture model by fucoidan was reported [22]. Moreover, recent studies have 
found that fucoidan enhanced epithelial barrier function via up-regulating the expression of the tight 
junction protein Claudin-1 [23]. 
Chitosan-based nanoparticles have been investigated in recent years for developing oral drug 
delivery carriers. However, the studies focused on preparing nanoparticles composed of a chitosan 
shell, thus the nanoparticles had the ablity to open the intestinal epithelial tight junctions. The 
nanoparticles were usually prepared by adding polyanions into excess amounts of chitosan solution to 
obtain nanoparticles covered with positively charged chitosan. In recent years, increased attention has 
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been focused on the development of chitosan/fucoidan (CS/FD) complex nanoparticles for drug 
delivery [24–30]. Our previous study developed a chitosan/fucoidan (FD) nanoparticle with chitosan 
dominant at an outer layer. The highly positively charged nanoparticles could open the tight junction 
for the transport of anti-angiogenic sulfated polysaccharides across Caco-2 cell monolayers. However, 
the aim of this work was to develop a berberine-loaded chitosan/FD-Tau nanoparticles for treatment of 
the defective intestinal TJ barrier induced by bacterial endotoxin. Because berberine could attenuate 
pro-inflammatory cytokine-induced tight junction disruption, it should be targeted to the intestinal 
epithelial Caco-2 cells, but not the sublayer macrophage cells. Thus, the nanoparticles were not 
designed to open the tight junction for transepithelial transport of berberine. 
To achieve the goal, FD was first conjugated with taurine (Tau) to obtain a fucoidan-taurine  
(FD-Tau) conjugate. Taurine can inhibit lipopolysaccharide-induced release of inflammatory factors to 
attenuate dysfunction in epithelial cells [31]. Moreover, the sulfonate group of taurine is a very strong 
acid which can increase the negative-charge density on fucoidan. Subsequently, a reverse of the 
CS/FD-Tau mixing process was developed to prepare negatively charged nanoparticles by adding CS 
solution into an excess amount of FD-Tau solution. This method was able to produce a FD-Tau-shelled 
nanoparticle because the excessive FD-Tau could be precipitated on the surface of the nanoparticles 
through the spontaneous formation of polyelectrolyte complex with chitosan. The nanoparticles shelled 
with FD-Tau are of benefit to the intestinal TJ barrier because fucoidan and taurine have been reported 
to attenuate dysfunction in epithelial cells. Furthermore, fucoidan can help the nanoparticles to target 
intestinal epithelial cells due to the fucose receptor on the epithelial cells. The prepared Ber-loaded 
CS/FD-Tau nanoparticles were then used for the treatment of defective intestinal epithelial TJ barrier 
caused by bacterial endotoxin. These nanoparticles were suitable to deliver berberine to epithelial 
Caco-2 cells without inducing the impairment of the intestinal barrier function. Berberine release from 
the nanoparticles could attenuate the intestinal epithelial impairment resulting from the inflammatory 
cytokine which was produced by endotoxin-activated macrophage. However, berberine could be 
delivered to the Caco-2 cell, thus the pro-inflammatory cytokines-mediated NF-κB signaling pathway 
in the cell could be inhibited and the epithelial TJ junction could be protected. 
Moreover, the pH-sensitivity property and berberine release behavior of the Ber-loaded CS/FD-Tau 
nanoparticles were investigated in simulated gastric fluid (SGF) and intestinal fluid (SIF). The effect of 
the nanoparticles on LPS-induced TJ barrier dysfunction was investigated by measuring transepithelial 
electrical resistance (TEER) and paracellular flux of fluorescein isothiocyanate-dextran (FITC-dextran) 
in an intestinal epithelial Caco-2 cells/macrophage RAW264.7 cells co-culture system. Redistribution 
of ZO-1 TJ proteins was observed using confocal laser scanning microscopy (CLSM). 
2. Results and Discussion 
2.1. Characterization of FD-Tau Conjugate 
A schematic diagram of the preparation of Ber-loaded CS/FD-Tau nanoparticles and construction of 
the Caco-2/RAW 264.7 cells co-culture system for estimating the protective effect of nanoparticles 
against LPS-caused barrier dysfunction is shown in Figure 1. Figure 2A shows the schematic diagram 
of the fucoidan-taurine (FD-Tau) conjugation reaction. FD-Tau conjugate was synthesized through 
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activation of carboxyl groups by EDC in MES buffer followed by the formation of amide bonds 
between the activated carboxyl groups of fucoidan and the amino groups of taurine. As shown in 
Figure 2B, the FTIR spectrum of fucoidan (FD) shows the absorption band due to asymmetric and 
symmetric stretching vibration bands of O=S=O (1246 cm−1) and C–O–S stretch (833 cm−1), indicating 
the presence of a sulfate ester linkage. The carbonyl stretch C=O of a carboxylic acid appears at  
1632 cm−1 and 1733 cm−1, indicating the presence of glucuronic acid in fucoidan. The FD-Tau 
conjugate demonstrated the asymmetric and symmetric stretching vibration bands of O=S=O at around 
1203 cm−1 due to the sulfonate groups on taurine, while a lower intensity shoulder near 1557 cm−1 is 
due to the formation of amide bonds after conjugation. These results indicated that taurine has been 
successfully coupled to fucoidan. TNBS assay of the fucoidan/taurine reaction mixture showed 71.3% 
of unreacted primary amine of taurine. Accordingly, the taurine substitution ratio of the FD-Tau 
conjugate was estimated to be 223 μg taurine/mg FD-Tau conjugate. 
Figure 1. Schematic diagram of the preparation of berberine (Ber)-loaded chitosan 
(CS)/fucoidan-taurine (FD-Tau) nanoparticles and construction of the human colon carcinoma 
cell line (Caco-2 cells)/murine macrophage cell line (RAW 264.7 cells) co-culture system 
for estimating the protective effect of nanoparticles against lipopolysaccharides (LPS)-caused 
barrier dysfunction.  
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Figure 2. (A) Schematic diagram of the fucoidan-taurine (FD-Tau) conjugation reaction; 
(B) Fourier transform infrared (FTIR) spectra of fucoidan, taurine, and fucoidan-taurine 
(FD-Tau) conjugate.  
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2.2. Characterization of Berberine-Loaded Nanoparticles 
Fucoidan is a polysaccharide extracted from marine brown seaweed which contains negatively 
charged sulfate and carboxyl groups. The electrostatic interactions between fucoidan and oppositely 
charged chitosan lead to the formation of stable colloidal nanoparticles. However, the nanoparticles 
were found to disintegrate in simulated gastric fluid (SGF, pH 2.0) rapidly because fucoidan contains 
carboxyl groups which are less acidic (pKa near 3.0). In this study, a FD-Tau conjugate was  
pre-synthesized to reduce the carboxyl groups and increase the more acidic sulfonate groups (pKa 1.5). 
Berberine is an isoquinoline alkaloid possessing a strong positive charge on its quaternary ammonium 
group. The FD-Tau conjugate was able to assemble with berberine to form stable Ber/FD-Tau 
Mar. Drugs 2014, 12 5682 
 
 
nanoparticles. The particle size of Ber/FD-Tau nanoparticles could be varied over a wide range by 
adjusting the weight ratio of berberine to FD-Tau. As shown in Table 1, the average particle size 
increased from 111.7 ± 2.7 to 156.3 ± 5.5 nm by decreasing the Ber/FD-Tau weight ratio from 2/1 to 
2/4. The zeta potentials were negative and also decreased with the decrease of the Ber/FD-Tau weight 
ratio, demonstrating that FD-Tau was increasingly exposed on the surfaces of the nanoparticles. The 
large polydispersity (PDI) of the Ber/FD-Tau nanoparticle systems indicated a wide range of  
particle size distribution. Moreover, berberine-loading efficiency was low (Table 1), suggesting that 
berberine was poorly retained in the nanoparticles because berberine and FD-Tau could not produce  
well-organized nanoparticles. 
Table 1. Average particle size, particle size distribution (polydispersity, PDI), zeta 
potential, berberine-loading content of Ber/FD-Tau nanoparticles prepared from berberine 
(Ber) (1.0 mg/mL, 1 mL) and fucoidan-taurine (FD-Tau) (0.5, 1.0, 1.5, 2.0 mg/mL, 1 mL) 
aqueous solution. 
FD-Tau 
(mg/mL) 
Ber/FD-Tau 
Weight Ratio 
Average Size 
(nm) 
Zeta Potential 
(mV) 
Drug Loading 
(%) 
PDI 
0.5 2/1 111.7 ± 2.7 –14.7 ± 1.4 10.3 ± 0.4 0.41 ± 0.01 
1.0 2/2 120.9 ± 4.1 –20.4 ± 0.7 13.1 ± 0.5 0.39 ± 0.02 
1.5 2/3 147.4 ± 4.8 –27.1 ± 0.9 9.7 ± 0.8 0.47 ± 0.01 
2.0 2/4 156.3 ± 5.5 –31.4 ± 1.8 12.8 ± 0.3 0.46 ± 0.02 
To enhance the berberine-loading efficiency of the nanoparticle system, chitosan was employed to 
form a polyelectrolyte complex with FD-Tau to obtain Ber-loaded CS/FD-Tau nanoparticles. We found 
that stable nanoparticles could only be prepared if both concentrations of berberine and FD-Tau were 
no more than 1.0 mg/mL. Therefore, the concentrations of berberine and FD-Tau were kept at 1.0 mg/mL 
in order to form a polyelectrolyte complex with chitosan. As shown in Table 2, the zeta potentials of 
the CS/FD-Tau nanoparticles were almost negative, suggesting that the reversed mixing process used 
in this study was able to produce FD-Tau-shelled nanoparticles because the excessive FD-Tau could be 
precipitated on the surface of the nanoparticles. The average particle size of Ber-loaded CS/FD-Tau 
nanoparticles increased noticeably when the chitosan amount was increased. In the presence of 
positively charged berberine, low-positively charged nanoparticles could be produced, depending on 
the chitosan/berberine/FD-Tau weight ratios (Table 2). Figure 3A shows the TEM micrographs of 
Ber/FD-Tau and Ber-loaded CS/FD-Tau nanoparticles. The Ber/FD-Tau nanoparticles are irregular in 
shape while the Ber-loaded CS/FD-Tau nanoparticles are spherical. Figure 3B shows the FTIR spectra 
of berberine, FD-Tau, chitosan and the Ber-loaded nanoparticles. The charcteristic bands of berberine 
at 1602 cm−1 (quaternary iminium ion, -C=N-) and 1505 cm−1 (C=C stretching vibration in the aromatic 
ring) are observed from the spectrum of the Ber-loaded nanoparticles. The characteristic peak of 
chitosan at 1589 cm−1 (the amino group, -NH2) and the absorption peak of fucoidan at 1632 cm−1 
(carboxylic ion, -COO−) respectively shift to 1602 and 1630 cm−1, accompanied by alteration in 
intensity of band signals. These results suggest that berberine was successfully incorporated in the 
nanoparticles through the formation of polyelectrolyte complex between fucoidan and chitosan. 
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Table 2. Average particle size, particle size distribution (polydispersity, PDI), zeta 
potential, berberine-loading content of Ber-loaded CS/FD-Tau nanoparticles (NPs) 
prepared from the mixed solutions (1 mL) of CS/Ber with different weight ratios and  
FD-Tau aqueous solution (1.0 mg/mL, 2 mL). 
CS/Ber 
(mg/mg) 
CS/Ber/FD-Tau 
Weight Ratio 
Average Particle 
Size (nm) 
PDI 
Zeta Potential 
(mV) 
Ber-Loading 
Content (%) 
CS/FD-Tau NPs 
0.5/0.0 1/0/4 225.6 ± 3.4 0.32 ± 0.02 −38.2 ± 1.4 − 
1.0/0.0 2/0/4 208.1 ± 5.5 0.35 ± 0.02 −35.7 ± 2.1 − 
1.5/0.0 3/0/4 204.5 ± 4.2 0.29 ± 0.02 −11.7 ± 1.7 − 
2.0/0.0 4/0/4 179.7 ± 3.9 0.33 ± 0.02 +17.1 ± 1.6 − 
Ber-loaded CS/FD-Tau NPs 
0.5/1.0 1/2/4 145.9 ± 2.7 0.27 ± 0.01 −13.1 ± 0.8 32.3 ± 0.4 
1.0/1.0 2/2/4 187.4 ± 6.2 0.21 ± 0.01 +7.6 ± 0.5 50.1 ± 2.5 
1.5/1.0 3/2/4 359.4 ± 4.7 0.39 ± 0.02 +15.6 ± 0.6 62.7 ± 3.4 
2.0/1.0 4/2/4 * − − − − 
*: Aggregation and precipitation of nanoparticles were found at CS/Ber/FD-Tau weight ratio of 4/2/4. 
Figure 3. (A) Transmission electron microscopy (TEM) micrographs of Ber/FD-Tau (a) 
and Ber-loaded CS/FD-Tau (b) nanoparticles; (B) FTIR spectra of FD-Tau conjugate, 
chitosan, berberine, and Ber-loaded nanoparticles. 
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2.3. Berberine Release 
The loading efficiency and PDI of the Ber-loaded CS/FD-Tau nanoparticles prepared at  
a CS/Ber/FD-Tau weight ratio = 2/2/4 were 50.1% ± 2.5% and 0.21 ± 0.01, respectively (Table 2). 
Therefore, the nanoaprticles with optimal drug loading and size distribution were chosen for drug 
release and cell culture. The sustained release profile of berberine from nanoparticles was investigated 
in the dissolution mediums of SGF (pH 2.0) and SIF (pH 7.4). Factors affecting the berberine release 
rate were the hydrophilicity and stability of various nanoparticle systems and the pH of the release 
medium. Fucoidan is a polysaccharide composed of sulfated esters of fucose and glucuronic acid. The 
pKa values of sulfate esters in sulfated fucose are around 1.5 while the pKa value of the carboxylate 
group in glucuronic acid is about 3.0. At pH 2.0, strong acid protonated the carboxylate ions (-COO−) 
in fucoidan, the polyelectrolyte complex of chitosan and fucoidan thus could be rapidly broken down [28]. 
After chemical modification, the carboxylate group decreased in amount but the sulfonate group 
increased due to the conjugation of taurine with the glucuronic acid residue of fucoidan. Accordingly, 
more negative charge was retained on the FD-Tau conjugate in SGF than on the original fucoidan.  
The burst release was not obvious because the positively charged berberine could form a strong 
electrostatic interaction with FD-Tau during the preparation of the nanoparticles. As shown in 
Figure 4, after 12 h of dissolution test at pH 2.0, there was only 31.2% berberine released from the 
Ber-loaded nanoparticles. Under these conditions, the protonaed chitosan (pKa value of the primary 
amine is around 6.5) and negatively charged FD-Tau conjugate can form stable and well-organized 
nanoparticles, thus providing a slow and continuous release of berberine. On the other hand, at neutral 
pH (pH 7.4), chitosan was deprotonated and berberine was rapidly released from the disintegrating 
nanoparticles [10]. It is worth noting that, at pH 7.4, the electrostatic attractions between chitosan and 
FD-Tau conjugate became weaker than those at pH 2.0 because chitosan was deprotonated. The 
nanoparticles released 85.7% of loaded berberine within 12 h (Figure 4). The result suggests that the 
CS/Tau-FD nanoparticles can release berberine in response to the change in pH value of the simulated 
gastrointestinal fluids. The intestinal pH (near neutrality) facilitates the release of berberine, indicating 
that the nanoparticles may be a potential intestinal delivery carrier for berberine. 
Figure 4. Cumulative release of berberine from nanoparticles at pH 2.0 (simulated gastric 
fluid, SGF) and pH 7.4 (simulated intestinal fluid, SIF). 
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2.4. Cytotoxicity of Berberine and Nanoparticles 
The berberine-free nanoparticles did not exhibit significant cytotoxicity. Cell viability of Caco-2 
cells was higher than 90% by treating the cells with 250 μg/mL nanoparticles (Figure 5A). Figure 5 
shows the dose-dependent cytotoxicity of Ber-loaded nanoparticles on Caco-2 cells. It was reported 
that cell viability of A549 cells incubated with CS/FD nanoparticles at a concentration below 3 mg/mL 
was higher than 80% [29]. Both berberine and Ber-loaded nanoparticles induced low cytotoxicity in 
the concentration range of 5–40 μg/mL as measured by the MTT assay (Figure 5B). Therefore, the 
nanoparticle samples were used at a Ber equivalent concentration of 30 μg/mL for the following studies. 
Figure 5. Dose-dependent cytotoxicity of berberine-free nanoparticles (A) and  
berberine-loaded nanoparticles (B) on Caco-2 cells. 
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2.5. Inhibition of NO and TNF-α Production 
Bacterial-derived lipopolysaccharides (LPS) can cause impaired barrier function, leading to a  
leak-flux diarrhea by enhancing uptake of antigen across the intestinal epithelium tight junction (TJ). 
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Most types of intestinal inflammation are associated with disorder of the intestinal epithelial TJ barrier 
function. LPS regulates proinflammatory cytokine which is produced by macrophage and can cause 
intestinal epithelial barrier dysfunction. The protective effect of Ber-loaded nanoparticles on epithelial 
barrier function of Caco-2 cell monolayer co-cultured with LPS-treated RAW 264.7 cells was 
evaluated by TEER and FITC-dextran permeability. 
Figure 6. (A) Nitric oxide (NO) and (B) TNF-α production in RAW264.7 cells stimulated 
by 100 ng/mL of LPS in presence of berberine-free nanoparticles (NPs) and berberine-loaded 
nanoparticles (Ber-loaded NPs) by adding 30 μg/mL berberine equivalent of the 
nanoparticles to the apical and basolateral sides respectively (n = 5). ** p < 0.01 compared 
with the control; ## p < 0.01 compared with the LPS-treated group. 
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To identify the protective effect of the Ber-loaded nanoparticles on the tight junction which was 
disrupted by inflammation, macrophages were incubated with the nanoparticles alone or in the 
presence of LPS. LPS is known to secrete inflammatory cytokines like TNF-α which are involved in 
immune responses and induces epithelial destruction [32]. LPS-stimulated nitric oxide (NO) production in 
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macrophage can be easily determined and used as an index of inflammation. As shown in Figure 6, 
without LPS, the presence of Ber-free nanoparticles (control) produced only low amounts of NO and 
TNF-α protein. Yet, the presence of PLS alone induced a large amount of them. As evidenced from 
Figure 6A, further addition of Ber-loaded nanoparticles to the basolateral side considerably inhibited 
NO production in LPS-activated macrophages. The reduction in NO production indicated that iNOS 
protein expression, a key factor in oxidant-induced disruption of intestinal Caco-2 monolayer barrier, 
was inhibited by the Ber-loaded nanoparticles. Moreover, the expression of TNF-α protein by  
LPS-activated macrophages was markedly inhibited by the Ber-loaded nanoparticles (Figure 6B). This 
agrees with the report from Jeong et al., that berberine could inhibit LPS-induced expression of 
proinflammatory genes in peritoneal macrophages and RAW 264.7 cells [33]. Besides, chitosan-based 
nanoparticles have been widely studied as drug carriers in mucosal and targeting drug delivery [34,35]. 
However, the addition of Ber-loaded nanoparticle to the apical side did not significantly reduce NO 
and TNF-α production by RAW 264.7 cells. The results suggest that the nanoparticles cannot 
effectively permeate through the TJ barrier to inhibit the inflammatory response in macrophage. The 
nanoparticles must be localized to macrophage and subsequently release berberine to inhibit the 
production of NO and pro-inflammatory cytokines by macrophage. 
2.6. Intestinal TJ Permeability 
As shown in Figure 7A, Ber-free nanoparticles or Ber-loaded nanoparticles alone did not result in 
reduction in TEER. The zeta potentials of the nanoparticles were −35.7 ± 2.1 and 7.6 ± 0.5 mV, 
respectively (Table 2). Berberine and fucoidan have been shown to improve intestinal barrier function 
and reduce intestinal epithelial permeability [6,23]. On the other hand, when the LPS (100 ng/mL) was 
applied to the basolateral compartment, it caused a significant decrease in TEER after 48 h incubation 
with the co-culture system of intestinal epithelial Caco-2 cells/macrophage RAW264.7 cells. However, 
the decrease in TEER induced by LPS-activated macrophage could be retarded by berberine treatment. 
To determine whether the Ber-loaded nanoparticles could reduce inflammation-induced TJ disruption, 
polarized Caco-2 monolayer was exposed to the nanoparticles after LPS treatment; and the TEER was 
monitored for 72 h. We found that the released berberine could effectively inhibit the LPS-induced 
disruption of TJ. For comparison, by adding Ber-free nanoparticles after LPS treatment, the decreasing 
trend of the TEER value was relatively close to that of the negative control group (LPS treatment). 
This indicated that the nanoparticles did not exhibit a significant protective effect on epithelial cell 
injury. Moreover, it was found that TEER values of Caco-2 monolayer exposed to the Ber-loaded 
nanoparticles 2 h before LPS treatment remained at a high level. These results suggested that the 
preventive effect of nanoparticles on LPS-induced destruction of the intestinal epithelial barrier was 
dependent on the incorporated berberine. 
LPS play an essential role in inducing inflammatory response in macrophages and the subsequent 
TJ disassembly in intestinal epithelia accompanied by an increase in paracellular permeability.  
The effect of LPS-induced intestinal epithelial barrier dysfunction was determined by measuring the 
paracellular flux of FITC-dextran. The permeability of TJ increased after stimulating the cell 
monolayer with LPS. As shown in Figure 7B, LPS caused a significant increase in the permeability 
coefficient (Papp) of FITC-dextran. The increase in FITC-dextran flux from the apical to the basal side 
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corresponded to the increase in the Caco-2 TJ permeability as indicated by the increased TEER. 
However, as the Caco-2 intestinal monolayer was co-treated with the LPS and Ber-loaded nanoparticles, 
the permeability of FITC-dextran through the Caco-2 cells was significantly reduced. The Ber-loaded 
nanoparticles thus lessened the increase of paracellular flux induced by LPS. These results indicated 
that Ber-loaded nanoparticles can be used to reduce the effects of LPS-induced impairment of 
epithelial barrier function. 
Figure 7. Epithelial barrier function determined by measurements of transepithelial 
electrical resistance (TEER) (A) and Fluorescein isothiocyanate (FITC) labeled dextrans 
(FITC-dextran) permeability (B). Caco-2 cell monolayers were co-cultured with 
RAW264.7 stimulated by 100 ng/mL of LPS in the presence of berberine (Ber), and 
berberine-free (NPs) and loaded nanoparticles (Ber-loaded NPs, 30 μg/mL berberine 
equivalent) (n = 5). ** p < 0.01 compared with the control; ## p < 0.01 compared with the  
LPS-treated group. 
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Although the above mentioned results suggested that the Ber-loaded nanoparticle cannot effectively 
permeate through TJ barrier to inhibit the production of NO and pro-inflammatory cytokines by 
macrophage (Figure 6A,B), the effect of the nanoparticles on attenuating inflammation-induced tight 
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junction dysfunction was significant (Figure 7A,B). Berberine is a traditional Chinese medicine used 
for the treatment of gastroenteritis and infective diarrhea. Berberine could be delivered to the Caco-2 
cell, but not to the sublayer macrophage, thus the pro-inflammatory cytokines mediating NF-κB 
signaling pathway in the cell could be inhibited to protect the TJ junction. In this study, the decrease in 
TEER and increase in paracellular permeability induced by LPS were moderated by Ber-loaded 
nanoparticles. Berberine has a considerable effect in decreasing intestinal epithelial permeability 
without affecting TJ proteins. Li et al., (2010) reported that berberine can inhibit pro-inflammatory 
cytokines such as TNF-α and IFN-γ induced intestinal epithelial tight junction damage [8]. Another 
study showed that increased intestinal permeability and tight junction disruption induced by LPS in 
mice could be efficaciously suppressed by berberine [6]. Those results revealed that berberine plays an 
important role in ameliorating intestinal epithelial TJ damage. On the other hand, fucoidan 
demonstrated superior immunomodulatory activity of suppressing TNF-α production in macrophage. 
Fucoidan also improves intestinal epithelial barrier function by reducing IL-8 gene expression and 
upregulating the expression of claudin-1 in Caco-2 cells [36,37]. Moreover, taurine is a potent 
compound against intestinal inflammation by repressing TNF-α induced Caco-2 cell damage [38]. 
Incorporation of berberine with the FD-Tau conjugate into the nanoparticle system was thus able to 
increasingly protect the intestinal epithelial barrier function under LPS-induced inflammation by 
macrophage, compared with berberine alone in solution (Figure 7A,B). Moreover, the Ber-loaded 
nanoparticles anchored with the mucoadhesive polymer, chitosan, might prolong the residence time of 
the nanoparticles on the intestinal mucous layer and subsequently localize the released berberine to the 
intestinal epithelial cells in an inflammatory bowel disease. 
2.7. Immunostaining of ZO-1 Protein 
LPS is known to induce intestinal barrier dysfunction and disruption of epithelial tight junction due 
to the production of pro-inflammatory cytokines such as TNF-α. The effect of TNF-α on the epithelial 
barrier function is associated with the redistribution of TJ proteins in polarized Caco-2 cell. Zonula 
occludens-1 (ZO-1) is a tight junction protein that links transmembrane proteins of the TJ to the actin 
cytoskeleton. As shown in Figure 8A, in the control group (without TNF-α), the stained Caco-2 cell 
visualized by CLSM exhibited a normally smooth ZO-1 distribution. Exposure of Caco-2 cells to  
TNF-α led to slight disruption of the TJ structure in polarized Caco-2 monolayers. The disrupted ZO-1 
proteins were not recovered after the removal of TNF-α, suggesting that the TJ was irreversibly 
disrupted by LPS. Treatment of the cells by the Ber-loaded nanoparticles prevented the TJ protein 
from disruption by TNF-α. The ZO-1 proteins remained intact after directly treating Caco-2 cells with 
TNF-α in the presence of the nanoparticles (Figure 8A). Several studies have demonstrated that 
berberine or fucoidan could directly induce changes in TJ protein expression, consequently improving 
intestinal epithelial barrier functions. 
ROS is known to induce disruption of intestinal epithelial barrier function [39,40]. CLSM was 
carried out to investigate the oxidative stress induced by LPS in RAW 264.7 cells and the ROS 
scavenging activity of the nanoparticles in the LPS-treated cells. The fluorescent images of 
intracellular ROS levels in RAW 264.7 cells after 24 h of incubation with LPS are shown in Figure 8B. 
The green fluorescence was from ROS-sensitive fluorescence dye (DCFDA) whereas the blue 
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fluorescence was from DAPI dye. The merged image of the fluorescence from DCFDA and DAPI 
dyes showed that the blue fluorescence in nuclei was surrounded by green fluorescence. Visualization 
of the green fluorescent signal in the cells indicated the production of intracellular oxidative stress by 
LPS. Pretreatment of the cells with 30 μg/mL berberine equivalent of nanoparticles quenched the green 
fluorescence of the ROS-sensitive dye in RAW 264.7 cells (Figure 8B). The nanoparticles therefore 
seemed to be a promising carrier to deliver berberine to scavenge the intracellular ROS in macrophage. 
Figure 8. (A) Confocal laser scanning microscopy (CLSM) visualization of protective 
effect of berberine in TNF-α induced epithelial barrier disruption. ZO-1 protein of Caco-2 
cells treated without (a) or with (b) berberine-loaded nanoparticles (Ber-loaded NPs) in the 
absence of TNF-α for 72 h; (B) CLSM visualization of intracellular ROS levels in RAW 
264.7 cells treated without (a) or with (b) berberine-loaded nanoparticles in the absence of 
LPS for 72 h. 
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3. Experimental Section 
3.1. Materials 
Lipopolysaccharides (LPS) from Salmonella enterica serotype typhimurium (L6143), Taurine,  
1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide hydrochloride (EDC), berberine, Dulbecco’s 
modified Eagle medium (DMEM), 2-(N-Morpholino)ethanesulfonic acid sodium salt (MES), Griess 
reagent, berberine, fluorescein isothiocyanate–dextran (FITC-dextran, 4000 kD), 2′,7′-Dichlorofluorescin 
diacetate (DCFDA), and MTT reagent were purchased from Sigma-Aldrich (St Louis, MO, USA). 
3.2. Synthesis and Characterization of Fucoidan-Taurine (FD-Tau) Conjugates 
FD-Tau conjugates were synthesized following a modified procedure described by Yu et al. [41]. 
Briefly, the carboxyl group on the glucuronic acid residues of fucoidan (MW 80 kDa, NOVA Pharma 
& Liposome Biotech Co., Ltd, Kaohsiung, Taiwan) was activated by EDC in MES buffer (25 mM,  
pH 5.0) and the activated fucoidan solution was added with an adequate amount of taurine (weight 
ratio of fucoidan/taurine/EDC = 1:1:1.5), and the resulting mixture was allowed to react for 48 h. Both 
reactions were quenched by adding hydroxylamine, and adjusting the pH of the reaction medium to 
8.0. The obtained FD-Tau polymer conjugates were dialyzed against water and then lyophilized. The 
purified products were analyzed by FTIR spectrometer (Perkin-Elmer Spectrum RX1, Waltham, MA, 
USA). The taurine substitution ratio of the FD-Tau conjugate was estimated by reacting free taurine 
with 2,4,6-trinitrobenzenesulfonic acid (TNBS) and subsequently measuring the absorbance at 420 nm. 
3.3. Preparation of Berberine-Loaded CS/FD-Tau Nanoparticles 
Berberine and FD-Tau solutions were prepared by respectively dissolving adequate amounts of 
berberine and FD-Tau in DI water. Berberine/FD-Tau nanoparticles were then prepared by adding the 
berberine solution (1.0 mg/mL, 1 mL) into the FD-Tau solution (0.5, 1.0, 1.5, 2.0 mg/mL, 1 mL) at 
various weight ratios (as shown in Table 1). Berberine-loaded CS/FD-Tau nanoparticles were prepared 
by dissolving chitosan (MW 60 kDa, deacetylation degree 85%, Koyo Chemical Co. Ltd. Hyogo, 
Japan) and berberine (1.0 mg/mL) together in DI water at different chitosan-to-berberine weight ratios 
(as shown in Table 2). Subsequently, the berberine/chitosan solution (chitosan/berberine weight  
ratio = 0.5 mg/1.0 mg, 1.0 mg/1.0 mg, 1.5 mg/1.0 mg, and 2.0 mg/1.0 mg, 1 mL) was added to the 
aqueous FD-Tau solution (1.0 mg/mL, 2 mL) to obtain self-assembled nanoparticles. A Malvern 
Zetasizer (3000HS, Worcestershire, UK) was used to measure the particle size and zeta potential of the 
nanoparticle suspensions. Transmission electron microscopy (TEM, Hitachi H-600, Tokyo, Japan) was 
used observe the morphology of nanoparticles after drying the suspension on a copper grid (300 mesh) 
coated with carbon film. 
3.4. In Vitro Release Study 
The nanoparticles were ultracentrifugated to remove free berberine molecules; and the loading 
efficiency (LE) was determined by measuring the concentration of free berberine in the supernatant 
using high performance liquid chromatography (HPLC) coupled with an ultraviolet (UV) absorption 
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detector operated at 360 nm. Quantification of berberine was performed using a reverse-phase C18 
column (150 mm × 4.6 mm, 5 μm), with a mobile phase of acetonitrile—0.04 M H3PO4  
(42:58 vol.%)—and a flow rate of 1.0 mL/min. Berberine release from the nanoparticles was 
investigated in SGF (0.01 N HCl, pH 2.0) and SIF (PBS, pH 7.4) at 37 C under agitation. Samples 
were collected at several pre-determined times. After centrifugation, the supernatants were used for 
berberine assay. The fraction of drug release was calculated based on the initial amount of berberine 
incorporated in the nanoparticles. The release study was repeated four times for each time point to 
obtain the average and standard deviation (SD). 
3.5. MTT Assay for Cell Viability 
The Caco-2 cell (BCRC 60182, Hsinchu, Taiwan) was maintained in DMEM medium containing 
10% fetal bovine serum (FBS), 1% penicillin (100 U/mL)-streptomycin (100 μg/mL), and 4mM 
glutamine. Caco-2 cells were cultured in 96-well plates at a density of 2 × 104 cells per well. 
Subsequent to adherence, berberine (5, 10, 20 and 40 μg/mL), Ber-loaded nanoparticles (the same 
berberine equivalents), Ber-free nanoparticles (25, 50, 100, 150, 200 and 250 μg/mL) were added to the 
cells and incubated for 24 h. After 48 h incubation at 37 C, the medium was aspirated and the cells 
were washed with PBS. The colorimetric determination of cell viability was performed by adding  
20 μL MTT solution (5 mg/mL) to each well. After 4 h of incubation, the culture medium was 
removed carefully. The supernatant was aspirated, and 100 μL dimethyl sulfoxide (DMSO) was added 
to dissolve the formazan crystal. The optical intensity of color (absorbance) was measured on a Perkin 
Elmer EnSpire 2300 multimode plate reader (PerkinElmer, Inc., Waltham, MA, USA) at 570 nm. 
Cytotoxicity was expressed as the relative viability (% control). 
3.6. Caco-2/Macrophage Co-Culture System 
Caco-2 cells were seeded at 4 × 105 cells/well and monolayers were grown in Costar Transwell  
6 wells/plates (Corning Costar Corp., NY, USA) with a 3 μm pore size filter insert. The electrical 
resistances of the filter-grown monolayers were measured using a Millicell®-Electrical Resistance 
System (Millipore Corporation, Billerica, MA, USA). Monolayers were maintained for 14–20 days in 
an atmosphere of 95% air and 5% CO2 at 37 C until the transepithelial electrical resistance (TEER) 
reached a value in the range of 900–1000 Ω cm2. RAW264.7 cells were seeded into the bottom plate at a 
density of 7.5 × 105 cells/well and the insert with polarized Caco-2 monolayer was added into the 
Transwell plate preloaded with RAW264.7 cells (BCRC 60001, Hsinchu, Taiwan). The anti-inflammatory 
effect of Ber-loaded nanoparticles was examined by addition of 100 ng/mL LPS to the basolateral side 
subsequent to adding 30 μg/mL berberine equivalent of the nanoparticles to the apical side. For 
comparison, 30 μg/mL berberine equivalent of the nanoparticles was directly added to the basolateral 
side (RAW264.7 cells). Nitric oxide and TNF-α productions were determined by culture supernatant 
collected from the basolateral side after 24 h. 
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3.7. Colorimetric Nitric Oxide Assay 
Griess reagent (0.1% N-(1-naphthyl)-ethylenediamine dihydrochloride and 1% sulfanilamide) was 
used to measure LPS-induced nitric oxide levels (NO) in RAW 264.7 macophage. At the end of 
incubation, 50 μL of Griess solution was added to the same volume of the supernatant for 10 min. The 
absorbance of the final product was measured at a wavelength of 540 nm using a Perkin Elmer EnSpire 
2300 multimode plate reader to determine the nitrite concentration with a calibration curve constructed 
using a standard solution of NaNO2. 
3.8. Enzyme-Linked Immunosorbent Assay (ELISA) for TNF-α 
Subsequent to LPS treatment, the TNF-α concentration in culture supernatant was determined by  
a sandwich enzyme-linked immunosorbent assay (ELISA). Thermo Scientific 96-well immunoplate 
was coated with anti-mouse TNF-α monoclonal antibody (R & D Systems) and blocked using 4% 
bovine serum albumin (BSA) in PBS. After the addition of 100 μL diluted sample to the wells, an  
anti-mouse TNF-α polyclonal antibody (R & D Systems, Minneapolis, MN, USA) was added to the 
ELISA plate. The plate was developed by horseradish peroxidase for 2 h and the color development 
was terminated with the addition of a 1 N H2SO4 solution. The absorbance was read at 450 nm using a 
Perkin Elmer EnSpire 2300 multimode plate reader (PerkinElmer, Inc., Waltham, MA, USA). 
3.9. Measurement of TEER and Paracellular Permeability 
S. typhimurium LPS (100 ng/mL, L6143, Sigma Chemical Co., St. Louis, MO, USA) was added to 
the basolateral side (cultured with RAW264.7 cells) of Transwell plate to induce the inflammatory 
response. The effect of the Ber-loaded nanoparticles on attenuating LPS-induced tight junction 
disruption was evaluated by adding 30 μg/mL berberine equivalent of the nanoparticles to the apical 
side (insert with Caco-2 cells monolayer). For comparison, the system in which the cells were not 
treated by LPS was used as a control. Moreover, the cells were pre-treated with 30 μg/mL berberine 
equivalent of the nanoparticles for 2 h, followed by adding LPS to RAW264.7 cells to induce  
tight junction damage in Caco-2 monolayer. Changes in TEER were measured using the above 
mentioned method. 
The transepithelial permeability was quantified by measuring the paracellular flux of fluorescein 
isothiocyanate (FITC) labeled dextrans (FITC-dextran). Transport of FITC-dextran (500 μg/mL in the 
apical compartment) across Caco-2 cell monolayer was quantitatively analyzed by measuring fluorescence 
intensity in the receiver compartment (basolateral side) at different time periods. The intensity of 
fluorescence emission (FL intensity) was determined by a Perkin Elmer EnSpire 2300 multimode plate 
reader, with excitation and emission wavelengths set to 488 and 519 nm, respectively. The amount of 
transported FITC-dextran was calculated using the calibration curve of FITC-dextran. The apparent 
permeability coefficient (Papp) was determined as follows: 
Papp (cm/s) = (ΔQ/Δt)/(A × C0) 
where ΔQ/Δt (μg/s) is the cumulative amount transported, A is the diffusion area (4.67 cm2), and C0 is 
the initial FITC-dextran concentration in the donor side (μg/mL). 
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3.10. CLSM Visualization of Immunostained TJ Protein 
Cells grown on glass cover slips in a 6-well plate were directly incubated with the pro-inflammatory 
cytokines, TNF-α (10 ng/mL), in the presence or absence of the Ber-loaded nanoparticles (30 μg 
berberine equivalent/mL). After removal of culture medium, cells were fixed with 3.7% paraformaldehyde. 
Subsequently, cells were permeabilized with 0.1% Triton X-100 at room temperature for 10 min.  
The cells were incubated with rabbit anti-ZO-1 monoclonal antibody (Zymed Laboraties, Inc., San 
Francisco, CA, USA) and subsequently stained by a Cy-3 conjugated goat anti-rabbit IgG (Jackson 
ImmunoResearch Laboratories, West Grove, PA, USA). Dislocation of ZO-1 protein in Caco-2 cells 
was examined under a confocal laser scanning microscopy (CLSM, Leica TCS SP2, Bensheim, 
Germany). To determine reactive oxygen species (ROS) induced by LPS (100 ng/mL) in RAW264.7 
cells, the culture medium was removed and the cells were washed with PBS. Subsequently, the cells 
were incubated in the dark with DCFDA (20 μM) which could passively diffuse across the cell 
membrane. The diacetate of nonfluorescent DCFDA was cleaved by intracellular esterase and then 
reacted with intracellular ROS to produce fluorescence. Fluorescence images of ROS generated in 
RAW264.7 cells were visualized using CLSM. 
3.11. Statistical Analysis 
All measurements were replicated three times and data were expressed as the mean ± standard 
deviation. Statistical analysis was performed by one-way analysis of variance and the determination of 
confidence intervals at p < 0.05 using SAS version 9.1 (SAS Institute, Cary, NC, USA). 
4. Conclusions 
In this work, Ber-loaded CS/FD-Tau nanoparticles were developed and acted as an epithelial 
protective material to prevent redistribution of TJ protein caused by bacterial endotoxin (LPS). The 
pH-responsive nanoparticles were stable at pH 2.0 but became unstable as the pH increased to 7.4. The 
release rate of berberine from the nanoparticle was slow in SGF but fast in SIF. Measurements of 
TEER and paracellular flux of FITC-dextran in Caco-2 intestinal monolayers showed that the  
Ber-loaded nanoparticles were able to diminish the LPS-induced increment in intestinal epithelial TJ 
permeability. CLSM confirmed that the Ber-loaded nanoparticles prevented redistribution of ZO-1 
proteins mediated by TNF-α induced TJ disruption. These findings suggested that the Ber-loaded 
nanoparticle is a potential carrier for site-specific delivery of berberine to the intestine for the 
inhibition of impaired intestinal barrier function. The nanoparticles might serve as an appropriate 
therapy for the treatment of disease associated with intestinal epithelial TJ dysfunction. 
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